Pharmacological treatment of schizophrenia;Psychopharmakologische Schizophreniebehandlung

Fortschritte der Neurologie Psychiatrie

Volumn 81, Issue 5, 2013, Pages

  Leucht, S ^a   Heres, S ^a   Kissling, W ^a   Davis, J M ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antipsychotic drugs; guideline; schizophrenia

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; LURASIDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

AGITATION; ARTICLE; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAINTENANCE THERAPY; MENTAL PATIENT; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT GAIN;

AGGRESSION; ANTIPSYCHOTIC AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; HUMANS; HYPNOTICS AND SEDATIVES; META-ANALYSIS AS TOPIC; PATIENT COMPLIANCE; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84878260982     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0033-1335405     Document Type: Article

References (200)

1. Adams C. E., Coutinho E., Davis J. M. et al. Cochrane Schizophrenia Group. The Cochrane Library. Chichester, UK John Wiley & Sons Ltd: 2008
2. Adams C. E., Fenton M. KP, Quraishi S. et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry: 2000; 179 190 199
3. Agid O., Kapur S., Arenovich T. et al. Delayed-onset hypothesis of antipsychotic action - a hypothesis tested and rejected. Archives of General Psychiatry: 2003; 60 1228 1235 (Pubitemid 37494076)
4. Agid O., Kapur S., Warrington L. et al. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research: 2008; 102 241 248
5. Akhondzadeh S., Tabatbaee M., Amini H. et al. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophrenia Research: 2007; 90 179 185 (Pubitemid 46177578)
6. Aleman A., Sommer I. E., Kahn R. S. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. Journal of Clinical Psychiatry: 2007; 68 416 421 (Pubitemid 46506807)
7. Alexander J., Tharyan P., Adams C. et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting - pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry: 2004; 185 63 69 (Pubitemid 38951631)
8. Allison D. B., Mentore J. L., Heo M. et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry: 1999; 156 1686 1696 (Pubitemid 29517559)
9. Altamura A. C., Velona I., Curreli R. et al. Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. International Journal of Psychiatry in Clinical Practice: 2002; 6 107 111 (Pubitemid 34601902)
10. Alvir J. MJ. Agranulocytosis: incidence and risk factors. Journal of Clinical Psychiatry: 1994; 55 137 138 (Pubitemid 24353038)
11. Andreasen N. C., Pressler M., Nopoulos P. et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry: 2010; 67 255 262
12. Arato M., O'Connor R., Meltzer H. Zeus study group Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia. International Clinical Psychopharmacology: 2002; 17 207 215
13. Ascher-Svanum H., Nyhuis A. W., Faries D. E. et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin: 2008; 34 1163 1171
14. Baldessarini R. J., Cohen B. M., Teicher M. H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry: 1988; 45 79 91 (Pubitemid 18018573)
15. Barbui C., Saraceno B., Liberati A. et al. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. European Psychiatry: 1996; 11 306 311
16. Barbui C., Signoretti A., Mule S. et al. Does the addition of a second antipsychotic drug improve Clozapine treatment? Schizophrenia Bulletin: 2009; 35 458 468
17. Barnes T. R., McPhillips M. A. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. International Clinical Psychopharmacology: 1995; 10 03 115 121 (Pubitemid 26054885)
18. Basan A., Kissling W., Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophrenia Research: 2004; 70 33 37 (Pubitemid 38916625)
19. Battaglia J., Moss S., Rush J. et al. Haloperidol, lorazepam, or both for psychotic agitation: a multicenter, prospective, double blind, emergency department study. American Journal of Emergency Medicine: 1997; 15 335 340
20. Baumann P., Hiemke C., Ulrich S. et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry: 2004; 37 243 265 (Pubitemid 39587052)
21. Bollini P. Antipsychotic drugs: is more worse? A meta analysis of the published randomized controlled trials. Psychological Medicine: 1994; 24 307 316 (Pubitemid 24158845)
22. Breier A., Hamilton S. H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological Psychiatry: 1999; 45 403 411 (Pubitemid 29130436)
23. Buchanan R. W., Ball M. P., Weiner E. et al. Olanzapine treatment of residual positive and negative symptoms. American Journal of Psychiatry: 2005; 162 124 129 (Pubitemid 40095681)
24. Buchanan R. W., Kreyenbuhl J., Kelly D. L. et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin: 2010; 36 71 93
25. Bushe C., Shaw M., Peveler R. C. A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology: 2008; 22 46 55
26. Carpenter W. T., Hanlon T. E., Heinrichs D. W. et al. Continuous vs. targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry: 1990; 147 1138 1163
27. Casey D. E., Daniel D. G., Tamminga C. et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology: 2009; 34 1330 1338
28. Casey D. E., Daniel D. G., Wassef A. A. et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology: 2003; 28 182 192
29. Chakos M., Lieberman J., Hoffman E. et al. Effectiveness of second generation antipsychotics for treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry: 2001; 158 518 526 (Pubitemid 32289814)
30. Chang J. S., Ahn Y. M., Park H. J. et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry: 2008; 69 720 731 (Pubitemid 351838681)
31. Chang Y. C., Lane H. Y., Yang K. H. et al. Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology: 2006; 26 554 559
32. Cheine M., Ahonen J., Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database of Systematic Reviews: 2001; Art No. CD000234
33. Chen E. YH, Hui C. LM, Lam M. ML et al. Maintenance treatment with quetiapine vs. discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. British Medical Journal: 2010; 341 c4024
34. Cheung H. K. Schizophrenics fully remitted on neuroleptics for 3-5 years-to stop or continue drugs? British Journal of Psychiatry: 1981; 138 490 494 (Pubitemid 11067000)
35. Chua W. L., Santiago A. D., Kulkarni J. et al. Estrogen for schizophrenia. Cochrane Database of Systematic Reviews: 2005; Art No. CD004719.
36. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry: 2007; 68 1876 1885
37. Conley R. R., Kelly D. L., Nelson M. W. et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology: 2005; 28 163 168 (Pubitemid 41134242)
38. Conley R. R., Tamminga C. A., Bartko J. J. et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry: 1998; 155 914 920 (Pubitemid 28307603)
39. Correll C. U., Leucht S., Kane J. M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. American Journal of Psychiatry: 2004; 161 414 415
40. Correll C. U., Malhotra A. K., Kaushik S. et al. Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry: 2003; 160 2063 2065 (Pubitemid 39619650)
41. Correll C. U., Rummel-Kluge C., Corves C. et al. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin: 2009; 35 443 457
42. Correll C. U., Schenk E. M. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry: 2008; 21 151 156 (Pubitemid 351339869)
43. Correll C., Agarwal V., Kane J. Gradual and Overlapping Antipsychotic Switch Strategies Are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-analysis of Different Switch Strategies. presented at the ACNP congress 2011
44. Crow T. J., MacMillan J. F., Johnson A. L. et al. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry: 1986; 148 120 127 (Pubitemid 16158512)
45. Davis J. M., Chen N. Dose-response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology: 2004; 24 192 208
46. Davis J. M. Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research: 1974; 11 65 69
47. Davis J. M., Chen N., Glick I. D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry: 2003; 60 553 564 (Pubitemid 36682312)
48. De Hert M., Dekker J. M., Wood D. et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry: 2009; 24 412 424
49. De Hert M., Detraux J., van Winkel R. et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol: 2011; 8 114 26
50. Dellva M. A., Tran P., Tollefson G. D. et al. Standard olanzapine versus placebo and ineffective dose olanzapine in the maintenance treatment of schizophrenia. PsychiatrServ: 1997; 48 1571 1577 (Pubitemid 27512385)
51. Ehrenreich H., Hinze-Selch D., Stawicki S. et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry: 2007; 12 206 220 (Pubitemid 46160985)
52. Elias A., Kumar A. Testosterone for schizophrenia. Database of Systematic Reviews: 2007; Art. No. CD006197.
53. Emsley R. A., Raniwalla J., Bailey P. J. et al. A comparison of the effects of quetiapine ("Seroquelo") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology: 2000; 15 121 131 (Pubitemid 30326047)
54. Essali A., Al-Haj H. N., Li C. et al. Clozapine vs. typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews: 2009; Art. No. CD000059.
55. Essock S. M., Schooler N. R., Stroup T. S. et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry: 2011; 168 702 708
56. Falkai P., Wobrock T., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry: 2005; 6 132 191
57. Fleischhacker W. W., Heikkinen M. E., Olie J. P. et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. European Psychiatry: 2008; 23 S114 S115
58. Gaebel W., Awad A. G. Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Wien Springer Verlag: 1994
59. Gaebel W., Falkai P., Weinmann S. et al. Behandlungsleitlinie Schizophrenie. Darmstadt Steinkopff: 2006
60. Gaebel W., Riesbeck M., Wölwer W. et al. Relapse prevention in first episode schizophrenia. Maintenance vs. intermittent drug treatment with a prodrome based early intervention: Results of a randomised controlled trial within the German research network on schizophrenia. Journal of Clinical Psychiatry: 2010; Published online: 29 June 2010 10.4088/JCP.09m05459yel
61. Gaebel W., Weinmann S., Sartorius N. et al. Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry: 2005; 187 248 255 (Pubitemid 41306106)
62. Gallego J. A., Robinson D. G., Sevy S. M. et al. Time to Treatment Response in First-Episode Schizophrenia: Should Acute Treatment Trials Last Several Months? J Clin Psychiatry: 2011; 72 1691 1696
63. Gallego J. A., Nielsen J., De Hert M. et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf: 2012; 11 527 542
64. Gardner D. M., Murphy A. L., O'Donnell H. et al. International consensus study of antipsychotic dosing. American Journal of Psychiatry: 2010; 167 686 693
65. Geddes J., Freemantle N., Harrison P. et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal: 2000; 321 1371 1376
66. Goodwin G., Fleischhacker W., Arango C. et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology: 2009; 19 520 532
67. Hajak G., Marienhagen J., Langguth B. et al. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychological Medicine: 2004; 34 1157 1163 (Pubitemid 39517146)
68. Hamann J., Leucht S., Kissling W. Shared decision making in psychiatry. Acta Psychiatrica Scandinavica: 2003; 107 403 409 (Pubitemid 36683414)
69. Hartung B., Wada M., Laux G. et al. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews.: 2005; Art. No. CD003443.
70. Hatta K., Otachi T., Sudo Y. et al. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res: 2011; 128 127 135
71. Hatta K., Otachi T., Sudo Y. et al. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res: 2012; 198 194 201
72. Herz M. I., Glazer W. M., Mostert M. A. et al. Intermittent vs. maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry: 1991; 48 333 339
73. Hiemke C., Baumann P., Bergemann N. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry: 2011; 44 195 235
74. Hogarty G. E., McEvoy J. P. Dose of fluphenazine, familial expressed emotions and outcome in schizophrenia. Archives of General Psychiatry: 1988; 45 797 805
75. Hogarty G. E., Ulrich R. F. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research: 1998; 32 243 250 (Pubitemid 28408287)
76. Hogarty G. E., Ulrich R. F., Mussare F. et al. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System: 1976; 37 494 500
77. Honer W. G., MacEwan G. W., Gendron A. et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry: 2012; 73 13 20
78. Hoyberg O. J., Fensbo C. Risperidone vs. perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica: 1993; 88 396 402
79. Huf G., Coutinho E. S., Adams C. E. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol vs. intramuscular haloperidol plus promethazine. British Medical Journal: 2007; 335 869
80. Huf G., Coutinho E. SF, Adams C. E. et al. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam vs. haloperidol plus promethazine. British Medical Journal: 2003; 327 708 711 (Pubitemid 37176750)
81. Jager M., Schmauss M., Laux G. et al. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study 3. European Psychiatry: 2009; 24 501 506
82. Jeste D. V., Lacro J. P., Gilbert P. L. et al. Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin: 1993; 19 817 830 (Pubitemid 23339438)
83. Johnson D. A. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica: 1976; 53 298 301
84. Johnson D. A., Ludlow J. M., Street K. et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry: 1987; 151 634 638 (Pubitemid 18025256)
85. Johnson D. AW. Further observation on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry: 1979; 135 524 530 (Pubitemid 10214526)
86. Jolley A. G., Hirsch S. R. Trial brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. 540 British Medical Journal: 1990; 301 837 842 (Pubitemid 20342782)
87. Jones P. B., Barnes T. RE, Davies L. et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry: 2006; 63 1079 1086
88. Joy C. B., Mumby-Croft R., Joy L. A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews: 2006; Art No. CD001257
89. Kahn R. S., Fleischhacker W. W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet: 2008; 371 1085 1097 (Pubitemid 351418005)
90. Kane J. M. Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry: 1982; 39 70 73 (Pubitemid 12163378)
91. Kane J. M., Correll C. U., Goff D. C. et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry: 2009; 70 1348 1357
92. Kane J. M., Davis J. M., Schooler N. et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry: 2002; 159 554 560 (Pubitemid 34274936)
93. Kane J. M., Honigfeld G., Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry: 1988; 45 789 796
94. Kane J. M., Khanna S., Rajadhyaksha S. et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology: 2006; 21 21 28 (Pubitemid 43175119)
95. Kane J. M., Leucht S., Carpenter D. et al. Optimising pharmacologic treatment of psychotic disorders. Journal of Clinical Psychiatry: 2003; 64 1 100
96. Kane J. M., Marder S. R., Schooler N. R. et al. Clozapine and haloperidol in moderately refractory schizophrenia - a 6-month randomized and double-blind comparison. Archives of General Psychiatry: 2001; 58 965 972 (Pubitemid 32937920)
97. Kane J. M., Meltzer H. Y., Carson W. H. et al. Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study vs. perphenazine. Journal of Clinical Psychiatry: 2007; 68 213 223 (Pubitemid 46362642)
98. Kane J. M., Rifkin A., Woerner M. et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry: 1983; 40 893 896 (Pubitemid 13025223)
99. Kapur S., Arenovich T., Agid O. et al. Evidence for onset of antipsychotic effects within the first 24h of treatment. American Journal of Psychiatry: 2005; 162 939 946 (Pubitemid 40676207)
100. Kinon B. J., Chen L., Ascher-Svanum H. et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research: 2008; a 102 230 240
101. Davis J. M., Mentalon L., Watanabe M. D. Depot antipsychotic drugs. Place in therapy. Drugs: 1994; 47 741 773 (Pubitemid 24151095)
102. Kinon B. J., Kane J. M., Johns C. et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacology Bulletin: 1993; 29 309 314 (Pubitemid 23311541)
103. Kinon B. J., Volavka J., Stauffer V. et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology: 2008; b 28 392 400
104. Kinon B. J., Chen L., Ascher-Svanum H. et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology: 2010; 35 581 590
105. Kishimoto T. New results alter balance of evidence of meta-analysis on long-acting injectable vs. oral antipsychotics in schizophrenia. Schizophr Bull: 2012; epub ahead of print.
106. Kishimoto T., Agarwal V., Kishi T. et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry: 2011
107. Kissling W., Kane J. M., Barnes T. R. et al. Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. In: Kissling W. (Ed.), Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Heidelberg, Berlin Springer: 1991; 155 163
108. Klein D. F., Davis J. M. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore Williams and Wilkins: 1969
109. Klein E., Kolsky Y., Puyerovsky M. et al. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biological Psychiatry 4: 1999; 6 1451 1454
110. Kleinberg D. L., Davis J. M., de Coster R. et al. Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology: 1999; 19 57 61 (Pubitemid 29047332)
111. Krakowski M. I., Czobor P., Citrome L. et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry: 2006; 63 622 629 (Pubitemid 43848293)
112. Lambert M., Schimmelmann B. G., Naber D. et al. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry: 2009; 42 277 283
113. Lecrubier Y., Quintin P., Bouhassira M. et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand: 2006; 114 319 27 (Pubitemid 44521299)
114. Lehman A. F., Lieberman J. A., Dixon L. B. et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry: 2004; 161 1 56
115. Leucht C., Heres S., Kane J. M. et al. (in press). Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research
116. Leucht S., Heres S., Kissling W. et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol: 2011; 14 269 284
117. Leucht S., Tardy M., Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet: 2012; 379 2063 2071
118. Leucht S., Cipriani A., Spineli L. et al. Multiple treatments meta-analysis on the efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. Lancet: 2013; accepted for publication.
119. Leucht C., Kitzmantel M., Chua L. et al. Haloperidol vs. chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews.: 2008; Art. No. CD004278.
120. Leucht S., Arbter D., Engel R. R. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry Published online: 8 January: 2008; 10.1038/sj.mp.4002136
121. Leucht S., Barnes T. RE, Kissling W. et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry: 2003; 160 1209 1222 (Pubitemid 41070936)
122. Leucht S., Busch R., Hamann J. et al. Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry: 2005; 57 1543 1549 (Pubitemid 40805384)
123. Leucht S., Busch R., Kissling W. et al. Early prediction of antipsychotic non-response. Journal of Clinical Psychiatry: 2007; 68 352 360
124. Leucht S., Corves C., Arbter D. et al. Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet: 2009; 373 31 41
125. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Journal of Clinical Psychiatry: 2006; 67 3 8 (Pubitemid 43837695)
126. Leucht S., Kane J. M., Etschel E. et al. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology: 2006; 31 2318 2325 (Pubitemid 44413213)
127. Leucht S., Kane J. M., Kissling W. et al. Clinical implications of BPRS scores. British Journal of Psychiatry: 2005; 187 363 371
128. Leucht S., Kane J. M., Kissling W. et al. What does the PANSS mean? Schizophrenia Research: 2005; 79 231 238
129. Leucht S., Kissling W., McGrath J. Lithium for schizophrenia. Cochrane Database of Systematic Reviews.: 2007; Art. No. CD003834.
130. Leucht S., Komossa K., Rummel-Kluge C. et al. A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry: 2009; 166 152 163
131. Leucht S., McGrath J., White P. et al. Carbamazepine augmentation for schizophrenia: how good is the evidence? Journal of Clinical Psychiatry: 2002; 63 218 224 (Pubitemid 34407081)
132. Leucht S., Pitschel-Walz G., Engel R. et al. Amisulpride - an unusual atypical antipsychotic. A meta-analysis of randomized controlled trials. American Journal of Psychiatry: 2002; 159 180 190 (Pubitemid 34126893)
133. Leucht S., Shamsi A. S., Busch R. et al. Early prediction of antipsychotic response - replication and six weeks extension. Schizophrenia Research: 2008; 101 312 319
134. Leucht S., Wahlbeck K., Hamann J. et al. New generation antipsychotics vs. low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet: 2003; 361 1581 1589 (Pubitemid 36578993)
135. Levine S. Z., Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin Advance Access: 2008
136. Levine S. Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry: 2010; 68 86 92
137. Lewis S. W., Barnes T. R., Davies L. et al. Randomized controlled trial of effect of prescription of clozapine vs. other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin: 2006; 32 715 723 (Pubitemid 44412859)
138. Lieberman J. A., Stroup T. S., McEvoy J. P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine: 2005; 353 1209 1223 (Pubitemid 41345943)
139. Lieberman J. A. Maximizing clozapine therapy: managing side effects. Journal of Clinical Psychiatry: 1998; 59 38 43 (Pubitemid 28196369)
140. Lin C. H., Chou L. S., Lin C. H. et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Journal of Clinical Psychiatry: 2007; 68 1522 1527
141. Lindenmayer J. P., Citrome L., Khan A. et al. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol: 2011; 31 160 8
142. Lindenmayer J. P., Khan A., Iskander A. et al. A randomized controlled trial of olanzapine vs. haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry: 2007; 68 368 379 (Pubitemid 46506800)
143. Marder S. R., Vanputten T., Mintz J. et al. Costs and benefits of 2 doses of fluphenazine. Archives of General Psychiatry: 1984; 41 1025 1029
144. McEvoy J. P., Hogarty G. E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Optimal dose of neuroleptic in acute schizophrenia: 1991; 48 740 745
145. McEvoy J. P., Lieberman J. A., Stroup T. S. et al. Effectiveness of clozapine vs. olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry: 2006; 163 600 610 (Pubitemid 44464569)
146. McGorry P. D. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry: 2005; 39 1 30
147. Moller H. J., Kissling W., Lang C. et al. Efficacy and side effects of haloperidol in psychotic patients: oral vs. intravenous administration. American Journal of Psychiatry: 1982; 139 1571 1575 (Pubitemid 13204455)
148. Muller N., Riedel M., Scheppach C. et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry: 2002; 159 1029 1034 (Pubitemid 34586950)
149. Naber D., Hippius H. The European experience with use of clozapine. Hospital and Community Psychiatry: 1990; 41 886 890 (Pubitemid 20315477)
150. NICE Schizophrenia: full national guideline on core interventions in primary and secondary care. National Institute for Clinical: Excellence Royal College of Psychiatrists. 2003
151. Newcomer J. W. Second-generation (atypical) antipsychotics and metabolic effects - a comprehensive literature review. CNS Drugs: 2005; 19 1 93 (Pubitemid 40677047)
152. Nolte S., Wong D., Latchford G. Amphetamines for schizophrenia. Cochrane Database of Systematic Reviews.: 2004; Art No. CD004964.
153. Odejide O. A., Aderounmu A. F. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry: 1982; 43 195 196 (Pubitemid 12117414)
154. Omori I. M., Wang J. Sulpiride vs. placebo for schizophrenia. Cochrane Database of Systematic Reviews: 2009; Art. No. CD007811.
155. Patel M. X., Taylor M., David A. S. Antipsychotic long-acting injections: mind the gap. British Journal of Psychiatry (Suppl.): 2009; 52 S1 S4
156. Paton C., Whittington C., Barnes T. R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine - a meta-analysis. Journal of Clinical Psychopharmacology: 2007; 27 198 204 (Pubitemid 46594939)
157. Pietzcker A., Gaebel W., Koepcke W. et al. Intermittent vs. maintenance neuroleptic long-term treatment in schizophrenia - 2 years results of a german
158. Premkumar T. S., Pick J. Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews: 2006; Art No. CD005962.
159. Rappard F., Müller N. Celecoxib Add-on Therapy Does Not Have Beneficial Antipsychotic Effects Over Risperidone Alone in Schizophrenia. Neuropsychopharmacology: 2004; 29 01 S222
160. Raveendran N. S., Tharyan P., Alexander J. et al. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine vs. intramuscular haloperidol plus promethazine. British Medical Journal: 2007; 335 865
161. Robinson D., Woerner M. G., Alvir J. M. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry: 1999; 56 241 247 (Pubitemid 29125132)
162. Rosenheck R., Cramer J., Xu W. C. et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine: 1997; 337 809 815 (Pubitemid 27391630)
163. Rosenheck R., Perlick D., Bingham S. et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - a randomized controlled trial. Journal of the American Medical Association: 2003; 290 2693 2702 (Pubitemid 37475597)
164. Rummel C., Kissling W., Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews.: 2006; Art No. CD005581.
165. Rummel-Kluge C., Komossa K., Schwarz S. et al. Second generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull.: 2012; 38 167 177
166. Sampath G., Shah A., Krska J. et al. Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology: Clinical and Experimental: 1992; 7 255 264
167. Schennach-Wolff R., Seemüller F. H., Mayr A. et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry: 2010; 196 460 466
168. Schooler N. R., Keith S. J., Severe J. B. et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Archives of General Psychiatry: 1997; 54 453 463
169. See R. E., Fido A. A., Maurice M. et al. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological Psychiatry: 1999; 45 1653 1656 (Pubitemid 29294106)
170. Sepehry A. A., Potvin S., Elie R. et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry: 2007; 68 604 610 (Pubitemid 46663044)
171. Shalev A., Hermesh H., Rothberg J. et al. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica: 1993; 87 86 91 (Pubitemid 23062195)
172. Shepherd M., Watt D., Falloon I. et al. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine (Suppl.): 1989; 15 1 46 (Pubitemid 19234086)
173. Simpson G. M., Mahmoud R. A., Lasser R. A. et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry: 2006; 67 1194 1203 (Pubitemid 44439690)
174. Singh S. P., Singh V., Kar N. et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry: 2010; 197 174 179
175. Siris S. G. Diagnosis of secondary depression in schizophrenia: Implications for DSM-IV. Schizophrenia Bulletin: 1991; 17 75 98
176. Smith R. C., Infante M., Singh A. et al. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. 2001; 4 239 250
177. Sommer I. E., de Witte L., Begemann M. et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry: 2012; 73 414 419
178. Sommer I. E., Begemann M. J., Temmerman A. et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull: 2012; 38 1003 1011
179. Stip E., Sepehry A. A., Chouinard S. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clinical Neuropharmacology: 2007; 30 218 229 (Pubitemid 47356719)
180. Stone J. M., Raffin M., Morrison P. et al. The biological basis of antipsychotic response in schizophrenia. Journal of Psychopharmacology: 2010; 24 953 964
181. Stroup T. S., Lieberman J. A., McEvoy J. P. et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry: 2007; 164 415 427 (Pubitemid 46513155)
182. Suzuki T., Uchida H., Watanabe K. et al. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? - a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berlin): 2007; 195 285 295 (Pubitemid 350045835)
183. Taylor D. M., Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica: 2009; 119 419 425
184. Tharyan P., Adams C. E. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews: 2005; Art No. CD000076.
185. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research: 2009; 109 10 14
186. Tiihonen J., Haukka J., Taylor M. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry: 2011; 168 603 9
187. Tollefson G. D., Beasley C. M., Tran P. V. et al. Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry: 1997; 154 457 465 (Pubitemid 27147597)
188. Tranulis C., Sepehry A. A., Galinowski A. et al. Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Canadian Journal of Psychiatry: 2008; 53 577 586
189. Trikalinos T. A., Churchill R., Ferri M. et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology: 2004; 57 1124 1130 (Pubitemid 39573018)
190. Tuominen H. J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews: 2006; Art No. CD003730.
191. Uchida H., Suzuki T., Takeuchi H. et al. Low dose vs. standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull.: 2011; 37 788 799
192. Volavka J., Czobor P., Sheitman B. et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry: 2002; 159 255 262 (Pubitemid 34126903)
193. Volz A., Khorsand V., Gillies D. et al. Benzodiazepines for schizophrenia. Cochrane Library, Wiley & Sons: 2007
194. Wahlbeck K., Cheine M., Essali A. et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry: 1999; 156 990 999 (Pubitemid 29302789)
195. Wang C. Y., Xiang Y. T., Cai Z. J. et al. Risperidone maintenance treatment in schizophrenia. A randomised, controlled trial. American Journal of Psychiatry: 2010; 167 676 685
196. Waraich P., Adams C., Hammill K. et al. Haloperidol dose for the acutely ill phase of schizophrenia. Cochrane Database of Systematic Reviews: 2002; Art. No. CD001951
197. Whitehead C., Moss S., Cardno A. et al. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychological Medicine: 2003; 33 589 599 (Pubitemid 36626041)
198. Wirshing D. A., Marshall B. D., Green M. F. et al. Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry: 1999; 156 1374 1379 (Pubitemid 29416533)
199. Wunderink L., Nienhuis F. J., Sytema S. et al. Guided discontinuation vs. maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry: 2007; 68 654 661 (Pubitemid 46841847)
200. Zimbroff D. L., Kane J. M., Tamminga C. A. et al. Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry: 1997; 154 782 791 (Pubitemid 27230100)